Key Takeaways
- CRISPR Therapeutics is expanding its global clinical infrastructure into Canada, with site selection underway at three academic medical centres.
- Casgevy (exa-cel), the world’s first approved CRISPR therapy, has received regulatory authorization in the UK, US, and EU Canada’s review is expected to complete in Q4 2026.
- Canadian sites under consideration include McMaster University Medical Centre, Toronto General Hospital, and the Montreal General Hospital.
- The Canadian gene editing competitive landscape includes Intellia Therapeutics’ in vivo programs and Editas Medicine’s ocular programs, none of which have Canadian-specific trial sites yet.
CRISPR Therapeutics (CRSP) the gene editing company co-founded in part by Canadian scientist Dr. Emmanuelle Charpentier and headquartered in Zug, Switzerland with major operations in Cambridge, Massachusetts is bringing its landmark sickle cell disease and beta-thalassemia program to Canadian soil. The company is in active discussions with three major Canadian academic medical centres to establish clinical sites for its Casgevy program, making Canada one of the first non-US, non-European markets to host CRISPR Therapeutics’ curative gene editing therapy.
Casgevy: The World’s First Approved CRISPR Therapy
Casgevy (exa-cel, or exagamglogene autotemcel) is a one-time gene editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The therapy uses CRISPR-Cas9 to edit patients’ own haematopoietic stem cells, reactivating fetal haemoglobin production and reducing or eliminating the clinical manifestations of both diseases. In the pivotal Phase 3 trials, 93.5% of SCD patients were free of severe vaso-occlusive crises for at least 12 consecutive months, and 89.4% of TDT patients achieved transfusion independence.
Casgevy received regulatory authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in November 2023 the world’s first CRISPR therapy approval followed by FDA approval in December 2023. The European Medicines Agency approved the therapy in February 2024. Health Canada received the New Drug Submission in January 2025 under the collaboration framework with the FDA, and a Q4 2026 authorization decision is expected.
| Company | Program | Mechanism | Indication | Status | Canadian Sites |
|---|---|---|---|---|---|
| CRISPR Therapeutics / Vertex | Casgevy (exa-cel) | Ex vivo CRISPR-Cas9 | SCD, TDT | HC review (Q4 2026 decision) | 3 under discussion |
| Intellia Therapeutics | NTLA-2001 | In vivo CRISPR (liver) | hATTR amyloidosis | Phase 3 | None yet |
| Intellia Therapeutics | NTLA-2002 | In vivo CRISPR (liver) | Hereditary angioedema | Phase 2/3 | None yet |
| Editas Medicine | EDIT-101 | In vivo CRISPR (eye) | Leber congenital amaurosis | Phase 1/2 | None yet |
| Beam Therapeutics | BEAM-101 | Base editing (ex vivo) | SCD | Phase 1/2 | None yet |
Canadian Site Selection: Hamilton, Toronto, Montreal
CRISPR Therapeutics is evaluating three Canadian sites for its Casgevy clinical and commercial administration program. McMaster University Medical Centre in Hamilton has the existing haematopoietic stem cell transplant infrastructure and patient catchment area to support a viable site. Toronto General Hospital, part of University Health Network, has Canada’s largest BMT program and serves a diverse urban population with a meaningful proportion of patients from SCD-prevalent ancestry groups. Montreal General Hospital offers bilingual clinical capacity and access to Quebec’s patient population.
Site certification for Casgevy requires qualification under a strict manufacturing and quality standard, as the therapy involves patient-specific cell editing performed in centralized manufacturing facilities before infusion. CRISPR Therapeutics’ manufacturing partner Lonza has committed to supplying Canadian sites through its US manufacturing facilities, with a backup supply arrangement from its European production site.
The Canadian Genomics Connection
The arrival of Casgevy in Canada has symbolic significance beyond its direct clinical impact. CRISPR technology was co-developed by Dr. Emmanuelle Charpentier, who completed foundational research on the CRISPR-Cas system while based in Canada during her time at the Université de Vienne and later collaborating with Canadian institutions. Canadian researchers at the University of Toronto, McGill, and the University of British Columbia have been active in CRISPR therapeutic development and the establishment of clinical sites for the world’s first approved CRISPR therapy creates training infrastructure and clinical expertise that will support Canada’s broader gene editing research ecosystem.
The Bottom Line
CRISPR Therapeutics’ expansion into Canadian clinical sites marks a maturation of the gene editing field from laboratory innovation to clinical reality with Canada as an early participant in the global rollout of the world’s first approved CRISPR therapy. For investors, the Canadian site establishment is a signal that Casgevy’s commercial rollout is proceeding on schedule globally, and that CRISPR Therapeutics is investing in the international infrastructure needed to support peak revenues from a therapy that could command $2-3 million per patient. The Health Canada decision expected in Q4 2026 will determine whether Canadian patients can access Casgevy domestically or must continue seeking authorization under the Special Access Program.